Healthcare ❯ Pharmaceuticals ❯ Drug Development
Eosinophilic Exacerbation Clinical Trials Antibody Drug Conjugates Hepatitis Delta Virus
The rare-disease specialist moves to add a Phase 3 hepatitis D antibody ahead of a 2026 efficacy readout.
